Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O14526
UPID:
FCHO1_HUMAN
Alternative names:
-
Alternative UPACC:
O14526; A6NHE6; A8K5U5; B4E120; Q05C93; Q8IW22
Background:
F-BAR domain only protein 1 plays a pivotal role in clathrin-mediated endocytosis, crucial for cellular processes such as nutrient uptake, signal transduction, and pathogen entry. It orchestrates membrane remodeling and protein recruitment for clathrin-coated pit formation, and modulates T-cell activation and proliferation by affecting TCR clustering and internalization.
Therapeutic significance:
Linked to Immunodeficiency 76, a disorder marked by recurrent infections and potential development of B-cell lymphoma or neurological symptoms, F-BAR domain only protein 1's involvement in immune response regulation highlights its therapeutic potential. Understanding its role could open doors to novel strategies for treating immunodeficiencies.